The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities
Abstract
This study investigated the relationship between plasma voriconazole concentrations (pVC) and risk of visual adverse events (VAEs) or liver function test (LFT) abnormalities using longitudinal logistic regression. Seven‐day mean pVC were calculated from 2925 plasma samples (1053 patients); in each 7‐day period, the presence or absence of VAEs/abnormal LFTs was analyzed as a binary outcome variable. There was a relationship between pVC and risk of VAE (P = .011) and a weaker, but statistically significant, association with risk of aspartate transaminase (AST), alkaline phosphatase (ALP), or bilirubin but not alanine transaminase (ALT) abnormalities. The odds ratios of LFT abnormalities per 1 μg/mL pVC increase ranged from 1.07 to 1.17. Maximum weekly occurrences were 10%, 8%, 5%, and 14% for AST, ALT, ALP, and bilirubin abnormalities, respectively. Receiver‐operating characteristic curve analysis indicates that individual pVC cannot be used to predict subsequent LFT abnormalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
Hanley, J. A., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063747 · Cited by 21,856
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Practical Statistics for Medical Research.
Walter, S. D., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,668
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationLiposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979 · cited 3×
“In clinical trials comparing voriconazole with conventional or liposomal amphotericin B, the rates of LFT abnormalities were comparable between the voriconazole and liposomal or conventional amphotericin B groups.(5,8,9,14) In a study to examine the efficacy and safety of voriconazole in the treatment of acute invasiv…”
BackgroundResultEfficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., DuPont, B., de la Torre‐Cisneros, J., Just‐Nubling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 680
Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens
Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J., & Kleinermans, D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2546-2553.2002 · Cited by 415
Self-citationMinari, A., Husni, R., Avery, R. K., Longworth, D. L., DeCamp, M., Bertin, M., Schilz, R., Smedira, N., Haug, M. T., Mehta, A., et al. (2002) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2002.t01-2-02002.x · Cited by 351
Ally, R., Schürmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P., Romero, A. J., & the Esophageal Candidiasis Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/322653 · Cited by 331 · cited 3×
“These events occurred with an overall frequency of approximately 30% in patients but were transient, rarely required drug discontinuation, and were fully reversible.(1,4-10) A mechanistic study using electroretinograms in healthy volunteers dosed at 300 mg twice daily for a period of 28 days confirmed that the effect…”
BackgroundNewer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
Shewanella algae and Shewanella putrefaciens: clinical and microbiological characteristics
Holt, H. M., Gahrn-Hansen, B., & Bruun, B. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01108.x · Cited by 277
Lazarus, H. M., Blumer, J. L., Yanovich, S., Schlamm, H., & Romero, A. (2002) · Journal of Clinical Pharmacology · doi:10.1177/0091270002424005 · Cited by 179
Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum, M. A., & Kuhn, D. M. (2002) · PubMed · Cited by 170
Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety
Purkins, L., Wood, N., Greenhalgh, K., Allen, M. J., & Oliver, S. D. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01993.x · Cited by 149
Self-citationThe pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent
Purkins, L., Wood, N., Greenhalgh, K., Eve, M. D., Oliver, S. D., & Nichols, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01992.x · Cited by 117
Self-citationPotoski, B. A., & Brown, J. E. (2002) · Clinical Infectious Diseases · doi:10.1086/343746 · Cited by 88
Safety of Voriconazole and Dose Individualization
Lutsar, I., Hodges, M. R., Tomaszewski, K. E., Troke, P. F., & Wood, N. (2003) · Clinical Infectious Diseases · doi:10.1086/374248 · Cited by 77
Self-citationTreatment of Systemic Fungal Infections in Patients with Hematologic Malignancies
B�hme, A., & Karthaus, M. (1999) · KARGER eBooks · doi:10.1159/000059318 · Cited by 2
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 716
Segal, B. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0808853 · Cited by 661
Metadata
- Authors
- Tan, K., Brayshaw, N., Tomaszewski, K., Troke, P., & Wood, N.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2006-02
- Volume
- 46
- Issue
- 2
- Pages
- 235-243
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1995236993
- Cited by
- 256
- References
- 20
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.